Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals diagnosed with any form of dementia (i.e., probable Alzheimer's Disease; vascular dementia; mixed; frontotemporal dementia)~2. Subjects who have met DSM-5 criteria for dementia (major neurocognitive disorder) who have instances of acute psychomotor agitation.~3. History of psychomotor agitation (e.g., kick, bite, flailing) to the point that it impairs social activities, requires staffing, or medical intervention, or impairs ability for functional activities of daily living.~4. Subjects are expected to exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior.~5. Subjects who have a score of ≤16 on the Mini-Mental State Exam (MMSE).~6. Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location.~7. Subjects who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR).~8. Subjects who are deemed to be medically appropriate for study participation by the principal investigator.~9. Subjects who are at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the study.~10. Subjects who have the capability to participate in the study and self-administer the investigational product.~11. Subjects who are on a stable concomitant medications regimen for the treatment of any concurrent conditions for at least one month prior to the screening visit.~Exclusion Criteria:~1. Subjects who have dementia associated with Parkinson's disease and/or Lewy Body Disease are excluded.~2. Subjects suffering from alcohol and/or substance abuse.~3. Subjects with agitation caused by acute intoxication must be excluded.~4. Subjects with significant risk of suicide or homicide per the investigator's assessment.~5. Subjects who have hydrocephalus, seizure disorder, or history of significant head trauma, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, or focal neurological findings, with a recent (1 year) large (non-microvascular) stroke who may be considered medically unstable or in recovery must be excluded.~6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years.~7. Subjects with laboratory or ECG abnormalities.~8. Subjects with serious, unstable, or uncontrolled medical illnesses must be excluded.~9. Subjects who have received an investigational drug within 30 days prior to Screening must be excluded.~10. Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving dexmedetomidine must be excluded.~11. Subjects whose agitation is attributed to pain or infection, delirium, concomitant medications, environmental conditions, or another psychiatric condition or medical condition as determined by the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 40 micrograms (Type: EXPERIMENTAL): Sublingual film containing 40 micrograms Dexmedetomidine
- 60 micrograms (Type: EXPERIMENTAL): Sublingual film containing 60 micrograms Dexmedetomidine
- Placebo (Type: EXPERIMENTAL): Sublingual Placebo film

Based on this trial design, predict the completion outcome and termination type (if applicable).